



Article

The Palladium(II) Complex of $A\beta_{4-16}$ as Suitable Model for Structural Studies of Biorelevant Copper(II) Complexes of N-Truncated Beta-Amyloids

Mariusz Mital ¹, Kosma Szutkowski ² , Karolina Bossak-Ahmad ¹ , Piotr Skrobecki ¹,
Simon C. Drew ¹ , Jarosław Poznański ¹ , Igor Zhukov ^{1,*} , Tomasz Frączyk ^{1,*}
and Wojciech Bal ^{1,*}

¹ Institute of Biochemistry and Biophysics, Polish Academy of Sciences, 02-106 Warszawa, Poland; 1988.mariusz.m@gmail.com (M.M.); karolina.bossak@gmail.com (K.B.-A.); skrobec@gmail.com (P.S.); scdrew1@gmail.com (S.C.D.); jarek@ibb.waw.pl (J.P.)

² NanoBioMedical Centre, Adam Mickiewicz University, 61-614 Poznań, Poland; kosma.szutkowski@outlook.com

* Correspondence: igor@ibb.waw.pl (I.Z.); tfraczyk@ibb.waw.pl (T.F.); wbal@ibb.waw.pl (W.B.); Tel.: +48-22-592-2038 (I.Z.); +48-22-592-2371 (W.B.)

Received: 12 November 2020; Accepted: 30 November 2020; Published: 2 December 2020



Abstract: The $A\beta_{4-42}$ peptide is a major beta-amyloid species in the human brain, forming toxic aggregates related to Alzheimer's Disease. It also strongly chelates Cu(II) at the N-terminal Phe-Arg-His ATCUN motif, as demonstrated in $A\beta_{4-16}$ and $A\beta_{4-9}$ model peptides. The resulting complex resists ROS generation and exchange processes and may help protect synapses from copper-related oxidative damage. Structural characterization of Cu(II) $A\beta_{4-x}$ complexes by NMR would help elucidate their biological function, but is precluded by Cu(II) paramagnetism. Instead we used an isostructural diamagnetic Pd(II)- $A\beta_{4-16}$ complex as a model. To avoid a kinetic trapping of Pd(II) in an inappropriate transient structure, we designed an appropriate pH-dependent synthetic procedure for ATCUN Pd(II) $A\beta_{4-16}$, controlled by CD, fluorescence and ESI-MS. Its assignments and structure at pH 6.5 were obtained by TOCSY, NOESY, ROESY, ¹H-¹³C HSQC and ¹H-¹⁵N HSQC NMR experiments, for natural abundance ¹³C and ¹⁵N isotopes, aided by corresponding experiments for Pd(II)-Phe-Arg-His. The square-planar Pd(II)-ATCUN coordination was confirmed, with the rest of the peptide mostly unstructured. The diffusion rates of $A\beta_{4-16}$, Pd(II)- $A\beta_{4-16}$ and their mixture determined using PGSE-NMR experiment suggested that the Pd(II) complex forms a supramolecular assembly with the apo-peptide. These results confirm that Pd(II) substitution enables NMR studies of structural aspects of Cu(II)- $A\beta$ complexes.

Keywords: Alzheimer's disease; $A\beta$ peptide; NMR spectroscopy; ¹³C relaxation; Palladium(II); ATCUN motif

1. Introduction

The $A\beta_{4-42}$ peptide is a major beta-amyloid species in the human brain. It was first co-discovered in 1985 as a major component of amyloid plaques of Alzheimer's Disease (AD) brains, and was found to be more abundant than the commonly studied $A\beta_{1-42}$ and $A\beta_{1-40}$ peptides [1,2]. However, this discovery was soon disregarded, and the research was focused on the latter two peptides as forming neurotoxic aggregates. $A\beta_{4-42}$ was ignored for more than two decades, until new analytical methods based on immunochemistry coupled with mass spectrometry revealed $A\beta_{4-42}$ as the major $A\beta$ species in various structures of healthy and AD brains [3,4]. $A\beta_{4-42}$ has been recently recognized as one of

the fastest aggregating A β peptides and, consequently, proposed to be a key source of toxic amyloid deposits [5–10].

A β peptides possess a number of metal-binding amino acid residues, but they are concentrated in the N-terminal part of their sequence, including Asp1, Asp7, Glu3, Glu11, His6, His13 and His14. On the basis of chemical and biological studies, Cu(II) ions in particular have been implicated in the neurotoxicity of A β peptides. The *logK* for Cu(II) binding to A β_{1-16} and A β_{1-40} peptides at a physiological pH of 7.4 was determined as 10.0 and 10.1, respectively [11].

A large volume of work was devoted to the effects of Cu(II) on the A β aggregation and production of deleterious reactive oxygen species (ROS) via the Cu(II)/Cu(I) catalytic redox couple [12–14]. The bulk of this work was, consequently, devoted to A β_{1-42} and A β_{1-40} peptides, and their C-terminally truncated models spanning the Cu(II) coordination site, A β_{1-28} and in particular A β_{1-16} peptides. The relevance of ROS production by the Cu(II)/Cu(I) redox process enabled by A β_{1-x} peptides was questioned, however, by the demonstration of a reverse relationship between the extent of A β_{1-x} aggregation and toxicity and their ability to generate ROS via Cu(II) complexes [15].

On the other hand, Cu(II) complexes of A β_{4-x} peptides are practically redox silent, as demonstrated in a ROS generation assay for A β_{4-42} and its non-aggregating model A β_{4-16} [16]. Moreover, the ascorbate activation ability of Cu(II)A β_{4-16} is marginal compared to that of Cu(II)-A β_{1-16} [17]. Furthermore, Cu(II)A β_{4-x} form high-affinity Cu(II) complexes (*log K* = 13.5 and 14.2 at pH 7.4, for *x* = 16 and 9, respectively [16,18]). A β_{4-16} was also able to withdraw Cu(II) ions from A β_{1-16} immediately and quantitatively [16], but, in contrast with A β_{1-x} peptides, strongly resisted copper transfer to metallothionein-3, except for under highly reducing conditions [19,20]. These properties prompted the concept that A β_{4-42} may serve a physiological purpose in the maintenance of synaptic transmission as a Cu(II) scavenger, as reviewed recently [21]. Furthermore, its hydrolytic product, A β_{4-9} is so inert to reduction by GSH that it may help shuttle Cu(II) ions across the blood–brain barrier [22].

These differences between the A β_{1-x} and A β_{4-x} peptides result from the different coordination modes they provide. The A β_{1-x} peptides bind the Cu(II) ion in a heterogeneous fashion, using the N-terminal amine of Asp1, and various combinations of His6, His13 and His14 imidazole nitrogens, and donor atoms of the Asp1-Ala2 peptide bond [23]. In contrast, the A β_{4-x} peptides take advantage of the truncation of the first three residues, which yields the so-called ATCUN/NTS motif, generated by Xaa-Yaa-His sequences, where the Cu(II) ion is coordinated to the N-terminal amine, the His imidazole and two intervening peptide nitrogens [24–26]. Although the Jahn-Teller effect in the *d*⁹ electronic structure of the Cu(II) ion stipulates a tetragonal symmetry with axial ligand(s), these are usually weakly bonded when strong nitrogen ligands occupy equatorial positions. As a result, such axial sites are often unoccupied or occupied by solvent (water) molecules, as seen in relevant X-ray structures [27,28]. This situation has also been reproduced in the square planar coordination geometry of the Cu(II) complex of the Phe4-Arg5-His6 ATCUN/NTS motif obtained from DFT calculations [16].

Taking into account the abundance of the A β_{4-42} peptide in the brain and its possible physiological role as a Cu(II) binding molecule, we considered that it would be very interesting to obtain a three-dimensional structure of the A β_{4-16} model peptide in the Cu(II)-complexed form. Unfortunately, Cu(II) is a paramagnetic metal ion, and despite significant progress in NMR techniques, it is not possible to obtain detailed structural data for such a small complex [29,30].

The ATCUN/NTS motif yields practically isostructural complexes for Cu(II) and all other metal ions capable of displacing peptide nitrogens, including Ni(II) [31,32], Pd(II) and Au(III) [33]. These three metal ions have *d*⁸ electronic configuration and their ATCUN/NTS complexes are square-planar and diamagnetic. Therefore, one of these metal ions can be used to substitute for Cu(II) in the A β_{4-16} complex in order to perform an NMR structural study. Pd(II) is our best choice, for its ability to form very stable peptide complexes by displacing hydrogen atoms from the side chains as well as main-chain nitrogens even under acidic conditions [33,34]. As a consequence of the very

high complex stability, they are also substantially more inert than the Cu(II) complexes, assuring the slow exchange condition in NMR experiments [34].

This paper describes structural and dynamic properties of the Pd(II) complex of the $A\beta_{4-16}$ peptide, investigated by NMR and additional techniques, including mass spectrometry, circular dichroism, and spectrofluorimetry. We demonstrate the usefulness of Pd(II) substitution for studies of the structure and reactivity of Cu(II) complexes of $A\beta_{4-x}$ peptides.

2. Results

2.1. Validation of the Pd(II) Complex as a Model for the Cu(II) Complex

Pd(II) is one of the most strongly hydrolysable cations, forming mononuclear $\text{Pd}(\text{OH})_2$ species at $\text{pH} \sim 1$ and polynuclear forms at $\text{pH} > 2$ [35]. In order to avoid the kinetic entrapment of Pd(II) in such hydroxides en route to the desired Cu(II)- $A\beta_{4-16}$ mimic, we used K_2PdCl_4 as the Pd(II) source, which can resist hydrolysis and polymerization up to $\text{pH} 5.5$ at appropriate temperatures and concentrations [36–38]. In control experiments, we observed precipitation of a red-brownish condensate after 8–10 h for samples containing 1 mM K_2PdCl_4 at $\text{pH} 4.5$. We, therefore, adopted a two-step preparation method of Pd(II) $A\beta_{4-16}$.

In the first step, the peptide was incubated at room temperature with substoichiometric (0.85 mol eq.) K_2PdCl_4 at $\text{pH} 4.0$, where the formation process of $\text{Pd}(\text{OH})_2$ and its polymerization to $[\text{Pd}(\text{OH})_2-x\text{Cl}_x]_n$ [39] was slower than the anchoring of Pd(II) to the peptide. The reaction was monitored using CD spectroscopy (Figure 1).




Figure 1. The formation of the 1:1 Pd(II) complex of $A\beta_{4-16}$ monitored by CD. (A) The 40 h evolution of CD spectra of the sample containing 0.3 mM $A\beta_{4-16}$ and 0.255 mM K_2PdCl_4 at $\text{pH} 4.0$ and room temperature. (B) The six-hour evolution of CD spectra of the same sample after the change of pH to 6.5. (C) The time dependence of ellipticity at 360 and 321 nm.

As shown in Figure 1, the initial anchoring of the Pd(II) ion to the peptide occurred promptly, as seen by an immediate appearance of chiral $d-d$ bands in the spectra at the first time point of 5 min. This initial spectrum containing at least three bands is gradually superseded by a simpler one,

containing two distinct d-d bands. The kinetics of formation of the latter has not been completed after 40 h. However, when NaOH was added to pH 6.5, the formation of a final reaction product was completed within about an hour and no hydroxide precipitation was observed. Therefore, we adopted a procedure in which the samples were incubated for 24 h at pH 4.0, followed by increasing the pH to 6.5, which was the standard value for most further experiments.

The samples prepared in this way were controlled by HPLC and major fractions were investigated by ESI-MS. Figure 2 presents an example of such data. Two major peaks contained uncoordinated $A\beta_{4-16}$ (at 27.2 min) and a monomeric $Pd(A\beta_{4-16})$ complex (at 37.7 min). Several minor peaks also contained the complex of the same stoichiometry. Both the peptide and the complex exhibited three charge species, 2+, 3+ and 4+ in electrospray ionisation mass spectrometry (ESI-MS) spectra, with roughly similar proportions of peak intensities. Figure 2 also presents the ion-mobility spectrometry–mass spectrometry (IMS-MS) spectra of 2+ and 3+ charge species of $A\beta_{4-16}$ and $Pd(A\beta_{4-16})$, showing very little difference in drift times between the peptide and its Pd(II) complex.




Figure 2. HPLC/MS characterization of products of the two-step procedure of obtaining the $Pd(A\beta_{4-16})$ samples. (A) HPLC chromatogram of the sample containing initially 0.5 mM $A\beta_{4-16}$ and 0.425 mM K_2PdCl_4 . (B) ESI-MS spectra of the respective HPLC peaks. (C) IMS characterization of $A\beta_{4-16}$ and $Pd(A\beta_{4-16})$ species at pH 6.5.

The next experiment compared the effect of Pd(II) and Cu(II) ions on Tyr10 fluorescence, a common tool in studying metal binding to $A\beta$ peptide [11,16]. In order to maintain a coherence between the Pd(II) and Cu(II) complexes, the samples were prepared in a different way. The required aliquots of stock solutions of Cu(II) salt were added directly to individual 25 μ M $A\beta_{4-16}$ samples dissolved in 20 mM MES buffer at pH 6.5, or 20 mM HEPES at pH 7.4. The Pd(II) samples were prepared using a two-step procedure: initially, appropriate Pd(II) solutions with $A\beta_{4-16}$ peptide were prepared in water, at pH 4, and incubated for 48 h. Next, the appropriate buffer was added to achieve a final solution with 20 mM MES, pH 6.5, or 20 mM HEPES, pH 7.4. The resulting titration curves, either for pH 6.5 (Figure 3) and 7.4 (Figure S1) indicate that both metal ions quench Tyr10 fluorescence in a similar stepwise manner. The straight lines in Figure 3 and Figure S1 are linear fits to the titration curve segments

corresponding to the binding of the metal ions at the 1st and 2nd binding sites, demonstrated for Cu(II) ions [16], and presumably equally valid for Pd(II).




Figure 3. $A\beta_{4-16}$ Tyr10 fluorescence ($\lambda_{ex} = 280$ nm, $\lambda_{em} = 303$ nm) quenching by Cu(II) (red dots) and Pd(II) (blue circles). Regions corresponding to the binding of the first and second metal ion equivalents are marked by dashed lines. $[A\beta] = 25$ μ M, $[MES] = 20$ mM, pH 6.5.

The results of the above experiments, taken together, strongly supported the assumption that Pd(II) may be an isostructural substitute for Cu(II) in the ATCUN/NTS motif of $A\beta_{4-16}$ for structural studies, forming a mononuclear 1:1 species at pH 6.5 and 7.4. Therefore, we performed a series of NMR experiments aimed at elucidating the solution structure of this complex.

2.2. Structural Analysis of the $A\beta_{4-6}$ Peptide as a Simple Model of the ATCUN/NTS Site in $A\beta_{4-16}$

The short Phe-Arg-His-amide (FRH) peptide represents the N-terminal residues forming the Pd(II) binding ATCUN/NTS motif. For structural and dynamic aspects of Pd(II) binding, two FRH samples—without the metal (*apo*) and saturated with Pd(II)—were used to perform homo- and heteronuclear NMR experiments. The acquired experimental data enabled the assignment of all ^1H and ^{13}C resonances in both (*apo* and Pd(II) saturated) forms (Tables S1 and S2). The ^1H - ^{13}C HSQC spectra recorded for the *apo* $A\beta_{4-6}$ and Pd($A\beta_{4-6}$) are presented in Figure 4. The amide $^1\text{H}^{\text{N}}$ signals of Arg5 and His6 were not detected due to fast exchange with water in the *apo* form, and coordination of the Pd(II) binding in the complex. In the ^1H - ^{15}N HSQC spectrum, only the signals from the NH_2 group at the Phe4 N-terminus were detected (Figure S3). Large downfield chemical shifts along the ^{13}C axis were observed for $^{13}\text{C}\alpha$ signals for Phe4 and Arg5, together with and ^1H shift for $^{13}\text{C}\alpha$ - $^1\text{H}\alpha$ in His6 (Figure 4A) confirmed that backbone amide groups facilitate the coordination sites for Pd(II) ion. The fourth site was determined from the analysis of the aromatic part of the ^1H - ^{13}C HSQC spectrum (Figure 4B) and selected as $^1\text{H}\epsilon_1$ proton in His6. The geometric parameters of the FRH complex with Pd(II) were extracted from the high-quality 3D structure of GGH tripeptide with Pd(II) ion [33]. Finally, the high-resolution 3D structure of FRH-Pd(II) complex (Figure 5) was solved by refined initial structure in water box with the YASARA software [40].




Figure 4. Overlay of the 2D heteronuclear ^1H - ^{13}C HSQC NMR spectra recorded for (A) aliphatic and (B) aromatic regions for $\text{A}\beta_{4-6}$ peptide in apo (red) and Pd(II) saturated (blue) forms. The assignments and changes in the position of the resonances are shown. The experiments were performed on Varian Inova 500 NMR spectrometer.




Figure 5. The 3D structure of Phe-Arg-His-amide (FRH) peptide represented the N-terminal ATCUN/NTS motif saturated with Pd(II) ion based on collected NMR constraints and crystallographic data available for GGH tripeptide [33].

To obtain information on molecular dynamic processes upon Pd(II) binding, the ^{13}C relaxation rates (R_1 and R_2) were measured for the ^{13}C resonances in Phe4 and His6 aromatic side-chains (Figure S4). The $^{13}\text{C}^\delta$ and $^{13}\text{C}^\epsilon$ resonances in the Phe4 side-chain did not reveal differences between the apo and Pd(II) cases, suggesting that they were not affected by Pd(II) binding. In contrast, the ^{13}C resonances in the His6 side-chain demonstrated substantial differences between both states, confirming the formation of the coordination bond in the His6 imidazole ring. The R_2 relaxation rate for $^{13}\text{C}^{\delta 2}$ was significantly decreased by Pd(II). At the same time, the Pd(II) binding stimulated the increase of R_1 relaxation rate for both His6 resonances— $^{13}\text{C}^{\epsilon 1}$ and $^{13}\text{C}^{\delta 2}$ (Figure S4, Table S3). Taking into account that the R_2 relaxation rate reflects the intensity of the dynamic processes in the low-frequency time frame (ms– μ s), we can conclude that Pd(II) binding resulted in shifting the molecular dynamics processes from the ms– μ s to the μ s–ns regime (Figure S4A,B).

2.3. Solution Structure of the Pd(II) Complex with the $A\beta_{4-16}$ Peptide

The $A\beta_{4-16}$ peptide together with the Pd($A\beta_{4-16}$) complex were subjected to structural analysis in solution based on NMR data. The combination of homonuclear and heteronuclear NMR spectra yielded the assignments of more than 95% of ^1H , ^{13}C and ^{15}N resonances in both forms (See Supporting Materials, Tables S4 and S5). In fact, in the apo $A\beta_{4-16}$ peptide, only amide protons in the three N-terminal residues were not observed, due to fast exchange with water protons. The resonances of His14 were not assigned due to degeneration of signals from His13 (Table S4). For the Pd($A\beta_{4-16}$) complex, the analysis of NMR data enabled us to assign practically all resonances, except for the amide protons of Phe4, Arg5 and His6, together with the $\text{H}^{\delta 1}$ proton in His6, which were displaced upon Pd(II) binding (Table S5).

Neither the $A\beta_{4-16}$ peptide nor the Pd($A\beta_{4-16}$) complex yielded a substantial amount of nontrivial long- and medium-distance constraints in homonuclear NOESY or/and ROESY experiments. Therefore, the 3D structure of apo $A\beta_{4-16}$ in solution was evaluated with the Xplor-NIH (version 2.39) software mostly on the basis of backbone ϕ and ψ torsion angles, deduced from chemical shifts with

the TALOS-N program [41]. The ensemble of 20 low-energy structures after additional refinement with the explicit solvent model demonstrated the existence of some structuring only in the His6–Tyr10 region (Figure S6).

The 3D structure of the complex $A\beta_{4-16}$ with an equimolar amount of Pd(II) reveals metal coordination according the ATCUN/NTS motif (Figure 6). Performed structural analysis suggest that Pd(II) bind to $A\beta_{4-16}$ in the same manner as to the $Pd(A\beta_{4-6})$. In comparison to the *apo* form, the equimolar complex of Pd(II) resulted in the small chemical shift perturbations (csp) detected for amide $^1H^N$ protons for the residues in $^7DSGYEVHHQK^{16}$ fragment of the $A\beta_{4-16}$ peptide. There are two sets signals observed for Tyr10 (Figure S5B), which suggests this residue exists in two conformations.




Figure 6. The 3D structure of $Pd(A\beta_{4-16})$ complex included the N-terminal ATCUN/NTS motif binding the Pd(II) ion.

2.4. Translational Mobility of $A\beta_{4-16}$ and $Pd(A\beta_{4-16})$ in Solution

The translational mobilities of the $Pd(A\beta_{4-16})$ complexes in solution were studied by diffusion measurements obtained at 11.7 T. The experimental data were analyzed on the basis of the Stejskal-Tanner equation [42]:

$$I = I_0 \exp(-D(G\gamma\delta)^2(\Delta - \delta/3))$$

where γ_H is the 1H gyromagnetic ratio, δ is the gradient duration, Δ is the diffusion time and G is the gradient strength. The coefficient of translational diffusion (D_{tr}) in solution was obtained for $A\beta_{4-16}$ peptide in *apo* form and for two concentrations of Pd(II) ions (Figure 7). The D_{tr} value obtained for the *apo*-peptide is $1.64 \pm 0.01 \times 10^{-10}$ (m^2/s), for the equimolar ratio in the $Pd(A\beta_{4-16})$ complex, the measured D_{tr} was $1.65 \pm 0.02 \times 10^{-10}$ m^2/s which corresponds to an effective hydrodynamic volume 7.42 (nm^3). The $Pd(A\beta_{4-16})$ complex 1:1.4 characterized D_{tr} equal to $1.34 \pm 0.02 \times 10^{-10}$ m^2/s , corresponding to the effective hydrodynamic volume 15.98 (nm^3), which is more than two times higher compared to *apo*- $A\beta_{4-16}$. The apparent hydrodynamic volume was calculated according to the Stokes–Einstein equation using a spherical approximation. Although the morphology of the diffusing species is not spherical, the proposal approximation is widely used to control the aggregation phenomena [43,44].




Figure 7. Integral attenuation vs. gradient amplitude in PGSE NMR experiment for $A\beta_{4-16}$ and $Pd(A\beta_{4-16})$ complex in solution. The *apo* $A\beta_{4-16}$ peptide (filled circles), equimolar $Pd(A\beta_{4-16})$ complex 1:1 (open circles) and 1:1.4 (open squares). The experiments were performed on a Varian Inova 500 NMR spectrometer.

3. Discussion

The CD and fluorescence spectroscopic and MS data strongly suggested that the Pd(II) ion accommodated the same ATCUN/NTS coordination structure in $A\beta_{4-16}$ as Cu(II). The evidence was indirect, however. For CD (Figure 1), it was based on the characteristic alternate pattern of Pd(II) $d-d$ bands, blueshifted, compared to the Cu(II) case, but retaining their symmetry [16]. For Tyr10 fluorescence, the same quenching pattern was seen for both metal ions (Figure 3), with the quenching just slightly more effective for the first Pd(II) equivalent. The correct stoichiometry indicating the replacement of four hydrogens by Pd(II) coordination was provided by ESI-MS (Figure 2A). In addition, the overlapping of the IMS drift peaks for the apo peptide and the complex is consistent with this view, because the lack of drift time difference indicates that the Pd(II) ion did not produce the long-range structuring in the molecule, and hence it had to be coordinated locally at one end of the molecule (Figure 2B).

These observations prompted the NMR study of the structure and dynamics of the $Pd(A\beta_{4-16})$ complex. However, while the observations presented above strongly suggested that the Pd(II) ion was bound selectively at the ATCUN/NTS Phe4-Arg5-His6 sequence, some binding at His13 and/or His14 residues could not be excluded *a priori*. Therefore, structural experiments were also performed using the Phe-Arg-His-amide tripeptide. This peptide has essentially one possible Pd(II) binding mode at weakly acidic pH, namely the ATCUN/NTS four-nitrogen complex, as evidenced by the X-ray study of its analogue Gly-Gly-His [33]. It could, therefore, serve as a positive control for the $A\beta_{4-16}$ experiments. The analysis of NMR spectra of the tripeptide complex, presented in Figures 4 and S3 confirmed the expected coordination mode. Very interestingly, the Pd(II) complexation did not affect the dynamics of the Phe4 side chain, but significantly elevated the longitudinal and decreased the transverse ^{13}C relaxation rates for the His imidazole ring. This observation is in line with the formation of the six-membered chelate ring formed by simultaneous coordination of His amide and His N1 nitrogens.

The experiments performed for the equimolar $Pd(A\beta_{4-16})$ sample confirmed the Pd(II) coordination in the 4N mode to the Phe-Arg-His sequence, and the lack of longer distance structuring in the coordinated peptide, as shown in Figure 6. In particular, there was no interaction between Tyr10

and the Pd(II) coordination site, which was previously detected for a generally similar Ni(II) complex with the N-terminal peptide of HP2 protamine [45]. In the structure of the Pd(II) binding site in the tripeptide Phe-Arg-His ($A\beta_{4-6}$) presented in Figure 5, no interactions between the Phe, Arg and His side chains are present. These side chains are located away from each other. In particular, there is no axial interaction of Phe4 π charge with the axial electronic density of the Pd(II). Such interaction was seen before in the NMR structures of di- and tripeptides containing a Tyr residue [46,47], but apparently is not sufficiently effective for the less polarized Phe aromatic ring. The positively charged guanidinium group of Arg5 appears to be fixed in its position by electrostatic interaction with the partial negative charge located on Pd(II)-coordinated amide nitrogens [45]. The Phe4 and Arg5 positions are also similar to those calculated previously for the Cu(II) complex with the $A\beta_{4-7}$ fragment by DFT [16]. The same structure was retained in Pd($A\beta_{4-16}$). The hydrogen bond between Phe4 and Asp7 postulated by previous DFT calculations was not detected.

The mobility of Pd($A\beta_{4-16}$) was studied in comparison to the *apo*-peptide, and also in the presence of the *apo*-peptide excess. Interesting observations were made in these experiments. In agreement with the IMS data, the Pd(II) coordination did not affect the peptide's hydrodynamic radius, thereby confirming the purely local character of the complexation on the peptide structure. A significant decrease in the complex mobility was observed, however, in the sample containing the complex and a 40% excess of the peptide. The apparent hydrodynamic radius calculated for this sample was about two-times larger than that for either the *apo*-peptide or the complex. This effect can be only explained by the supramolecular assembly between the complex and the *apo*-peptide. The absence of changes in chemical shifts of the Phe-Arg-His sequence upon *apo*-peptide addition indicates that no coordinative bridging by Pd(II) occurred. Two possible mechanisms for this effect can be considered. As the square-planar Pd(II) chelate structure is the only permanent and significant difference between the complexed peptide and the *apo*-peptide, one possible interaction involves its dipolar interaction with aromatic residues of the *apo*-peptide, similar to the interaction observed between the isoelectronic Ni(II) complex of the Arg-Thr-His N-terminus and the Tyr phenol ring in the HP2 pentadecapeptide [45]. In general, many types of stacking interactions that have been observed in various Cu(II) and Pd(II) biomimetic complexes might occur in the investigated system [48]. Another may stem from electrostatics, as proposed recently in studies of Cu(II) effects on fibrillization of $A\beta_{1-40}$ and $A\beta_{4-40}$ peptides [49]. The electrostatic charges of $A\beta_{4-16}$ and Pd($A\beta_{4-16}$) at pH 6.5 can be calculated from the data presented before for the Cu(II) complex, reasonably assuming that the Cu(II)/Pd(II) replacement did not affect the acidities of the peptide's residues. The average charges of these two species are +1.1 and +0.5, respectively. If, however, we consider the +1 charge at the C-terminal Lys residue in both molecules, then we see that there is a slight electrostatic incentive for the attractive interaction specifically between the *apo*-peptide and the complex spread over the rest of the molecule. Probably, both kinds of interactions occur, enabling the formation of the heterodimer or even higher order assemblies, even despite the lack of defined structure in free and Pd(II)-complexed $A\beta_{4-16}$. These results confirm the suitability of Pd(II) substitution to study structural aspects of Cu(II) complexes of $A\beta$ peptides and suggest that the molecular pathway of their aggregation processes may lead via interactions of their N-termini.

4. Materials and Methods

4.1. Materials

The $A\beta_{4-16}$ (FRHDSGYEVHHQK-amide) and $A\beta_{4-6}$ (FRH-amide) peptides were synthesized according to Fmoc strategy as described previously [16]. K_2PdCl_4 , NaOH, HCl and acetonitrile (HPLC grade) were purchased from Sigma-Aldrich. D_2O was purchased from Armar Chemicals.

4.2. Sample Preparation

A portion of lyophilized $A\beta_{4-16}$ peptide was diluted in MQ water. The concentration of this stock solution was determined using $\epsilon_{275} = 1375 \text{ M}^{-1}\text{cm}^{-1}$ [16]. Pd(II) was added to the sample from a 100 mM K_2PdCl_4 stock of to obtain a peptide-to-metal ratio of 1:0.85. The pH of the sample was then increased by adding small amounts of concentrated NaOH up to pH 4, and then handled further, as required by specific experimental methods.

4.3. Mass Spectrometry

The samples prepared as above, containing 0.5 mM $A\beta_{4-16}$ and the peptide-to-Pd(II) ratio of 1:0.85 were incubated for a further 24 h at pH 4. Then, the pH was set to 6.5 using concentrated NaOH. 100 μL samples were injected into the HPLC system (Empower, Waters), equipped with an analytical C18 column ($4.6 \times 250 \text{ mm}$). The eluting solvent A was 0.1% (*v/v*) TFA in water, and solvent B was 0.1% (*v/v*) TFA in 90% (*v/v*) acetonitrile. The chromatograms were obtained at 220 and 280 nm. Individual peaks were collected and measured by ESI-MS on a ESI Q-ToF Premier mass spectrometer (Waters). The samples were injected at a 40 mL/min flow rate and MS spectra were recorded in positive ion mode during 5 min in the range *m/z* of 500–1800. Obtained mass spectrometry data were analyzed and processed using MassLynx (Version 4.1, Waters Inc., Milford, MA, USA). Ion mobility (IMS-MS) experiments were performed using a Synapt G2 HDMS instrument (Waters). Ions were generated using nanoelectrospray ionization at 1.7 kV from PicoTip emitters 2 μm i.d. (QT10-70-2-CE-20 New Objective). MS settings were adjusted to obtain an optimal ion transmission as follows: 30 V sampling cone, 5 V extractor cone, 40 °C source temperature, 10 V trap collision energy, and 5 V transfer collision energy, wave height and wave velocity were set as 40 V and 800 m/s, respectively. Drift times were obtained by generating an extracted ion chromatogram (XIC) from the arrival time distribution function in MassLynx v4.1 using the monoisotopic mass and a mass window of $\pm 0.075 \text{ Da}$.

4.4. Circular Dichroism

CD experiments were carried out on the J-815 CD spectrometer (JASCO) over the spectral range of 250–600 nm, using a 1 cm path length quartz cuvettes. Measurements were performed at 25 °C for samples containing 0.3 mM $A\beta_{4-16}$ and the peptide-to-Pd(II) ratio of 1:0.85. The spectra were recorded in 40 min intervals, starting immediately after sample preparation, until the reaction neared equilibrium after 40 h. Next, the pH was set to 6.5 using NaOH and spectral changes were recorded at 30 min intervals for another six hours.

4.5. Spectrofluorimetry

Fluorescence spectra of $A\beta_{4-16}$ in the presence of Cu(II) and Pd(II) ions were recorded at 25 °C using a FP-6500 spectrofluorometer (Jasco). The excitation wavelength was 280 nm; the emission spectra were in the range of 290–400 nm. Solutions of metal ions and the peptide were combined in varying metal/peptide ratios, with a constant $A\beta_{4-16}$ concentration of 25 μM , in 20 mM MES buffer, pH 6.5, or 20 mM HEPES buffer, pH 7.4. Cu(II) salt solution was added directly to the prepared peptide solution in the respective buffer. Pd(II) was added to water solutions of the peptide at pH 4, then incubated for 48 h. Next, to such solutions, appropriately concentrated buffer solutions were added to obtain concentrations analogous to Cu(II) samples. Each sample was prepared in triplicate.

4.6. NMR Spectroscopy

The Pd(II)-containing samples were prepared by incubation for 24 h at room temperature at $\text{pH} \approx 4.0$. Next, the samples were diluted with D_2O to obtain a 10% (*v/v*) solution of the latter, followed by adjustment of pH to 6.5 with a small amount of concentrated NaOH. The samples of the apo $A\beta_{4-6}$ and $A\beta_{4-16}$ peptide was prepared directly in 90%/10% (*v/v*) $\text{H}_2\text{O}/\text{D}_2\text{O}$, at pH 6.5. The final volumes of the samples were 300 μL , with final peptide concentrations between 1.0 and 2.5 mM.

The measurements were conducted on Agilent DDR2 800 (^1H frequency 799.903 MHz), Agilent DDR2 600 (^1H frequency 599.930 MHz), and Varian Inova 500 (^1H frequency 500.606 MHz) NMR spectrometers operated at magnetic fields of 18.8 T, 14.1 T, and 11.7 T, respectively. All spectrometers were equipped with three channels, z -gradient unit and $^1\text{H}/^{13}\text{C}/^{15}\text{N}$ probehead with inverse detection. The homonuclear 2D NMR experiments included TOCSY acquired with mixing times of 15, 80, and 90 ms, ROESY conducted with the mixing time of 300 ms, and NOESY with mixing times of 150 and 300 ms. Homonuclear experimental data sets were supplemented with heteronuclear 2D ^1H - ^{13}C HSQC (tuned independently to aliphatic and aromatic regions) as well as 2D ^1H - ^{15}N HSQC NMR experiments acquired using the natural abundance of ^{13}C and ^{15}N isotopes. All NMR data sets were referenced indirectly in respect to external sodium 2,2-dimethyl-2-silapentane-5-sulfonate (DSS) with the Ξ coefficients equal to 0.251449530 and 0.101329118 for ^{13}C and ^{15}N dimensions, respectively [50]. The acquired data sets were processed with the NMRPipe program [51] and analyzed with the Sparky software [52].

4.7. Assignment of the ^1H , ^{13}C and ^{15}N Resonances and 3D Structure Evaluation of $A\beta_{4-16}$ Peptide and $\text{Pd}(A\beta_{4-16})$ Complex in Solution

The ^1H , ^{13}C and ^{15}N resonance assignments were obtained using base standard procedure on base analysis 2D homonuclear (NOESY, TOCSY) and heteronuclear (^1H - ^{13}C and ^1H - ^{15}N HSQC) spectra. More than 90% of resonances were successfully assigned (Tables S4 and S5). Unfortunately, the collected 2D NOESY and ROESY data sets did not provide nontrivial medium- or long-range distance constraints. Nevertheless, the analysis of ^1H , ^{13}C and ^{15}N chemical shifts performed with the TALOS-N software [41] yielded 16 and 8 backbone ϕ and ψ torsion angles predicted for $A\beta_{4-16}$ peptide in apo and Pd(II)-saturated forms, respectively. Additionally, the χ_1 torsion angles of the side chains were predicted in six and four residues in $A\beta_{4-16}$ peptide and $\text{Pd}(A\beta_{4-16})$ complex, respectively (Tables S6 and S7). Both 3D structures were solved by the Xplor-NIH 2.37 program [53]. The slightly modified standard protocol included in Xplor-NIH distribution (protG.inp) was used for 3D structure evaluation. Briefly, the 200 randomly generated structures which were subjected to 12 ns cartesian molecular dynamic simulation at 2000 K followed by 3000 steps of simulating annealing included slow cooling to the temperature 100 K. The refined procedure in the explicit solvent were performed for the 20 lowest-energy structures with the YASARA software utilizing AMBER14 force field during the 3000 steps of simulating annealing procedure in water solvent [40]. In the case of $\text{Pd}(A\beta_{4-16})$ complex, the parameters for Pd(II) ion (bond length and angles) were taken from the crystal structure of Pd(II) complex with the GGH tripeptide [33]. The evaluated 3D structures were visualized and analyzed with the MOLMOL [54] and Chimera [55] software.

4.8. ^{13}C Relaxation Measurements

The ^{13}C R_1 and R_2 relaxation data were acquired on Varian Inova 500 NMR spectrometer for FRH peptide in both (apo and Pd(II) saturated) at natural abundance of ^{13}C isotope. The experiments were conducted utilizing the pulse sequence included in BioPack (Agilent Inc., PaloAlto, CA, USA). The 32 scans were enabled to achieve a reasonable signal-to-noise ratio for collected points in R_1 and R_2 measurements. The R_1 relaxation data were obtained as 5 delays—10, 50, 110, 190, and 290 ms. The R_2 relaxation rates were recorded with 5 delays—10, 30, 50, 70, and 90 ms. The recycling delay was set to 3 s.

4.9. Diffusion Measurements

Diffusion experiments were carried out on a Varian Inova 500 NMR spectrometer utilizing a standard PGSE (Pulsed Gradient Spin Echo) pulse sequence [56] supplemented with Excitation sculpting Solvent Suppression block [57] were applied as 25 gradients with an effective gradient pulse duration (δ) as long as 3 ms. The diffusion measurements for $A\beta_{4-16}$ saturated with Pd(II) were performed using diffusion time (Δ) of 100 and 150 ms in the case of Pd(II) concentrations 1

and 1.4. The 128 accumulations were performed with a relaxation delay of 3 s in order to increase the signal-to-noise ratio. The obtained experimental data were Fourier transformed with a 2 Hz line broadening factor applied. For extraction of the translation diffusion coefficient (D_{tr}), the signals observed between 0–3 ppm were integrated and then exported to the Origin software together with gradient amplitudes. The D_{tr} values were extracted by fitting using the Stejskal–Tanner equation [42] taking into account an additional correction for the Δ delay during BPP pulse in sequence (delay between gradient δ and $\pi/2$ pulse was equal to 0.5 ms).

5. Conclusions

Our study demonstrated that by Pd(II) substitution working models of Cu(II) complexes of ATCUN/NTS peptides, including those of the $A\beta_{4-x}$ family, suitable for direct structural and functional studies can be obtained. Already in this pioneering study, the diffusion coefficient determination, essentially impossible for the paramagnetic Cu(II) complex empowered us to confirm a supramolecular interaction contributing to the control of aggregation and fibrillization of the $A\beta$ peptides. This interaction is a prerequisite for a better understanding of the molecular events leading to Alzheimer's disease and thereby finding key markers of the disease.

Supplementary Materials: The following are available online at <http://www.mdpi.com/1422-0067/21/23/9200/s1> Table S1: ^1H , and ^{13}C chemical shifts assigned for the *apo* $A\beta_{4-6}$ peptide at 298 K on Varian Inova 500 NMR spectrometer. Table S2: ^1H , and ^{13}C chemical shifts assigned for the Pd($A\beta_{4-6}$) complex at 298 K on Varian Inova 500 NMR spectrometer. Table S3: The ^{13}C R_1 and R_2 relaxation rates extracted for the aromatic carbons in the FRH peptide acquired on natural abundance of ^{13}C isotope. The NMR experiment performed at 298 K on Varian Inova 500 NMR spectrometer. Table S4: ^1H , ^{13}C , and ^{15}N chemical shifts assigned for *apo* $A\beta_{4-16}$ peptide at 298 K on Agilent DDR2 800 NMR spectrometer. Table S5: ^1H , ^{13}C , and ^{15}N chemical shifts assigned for Pd($A\beta_{4-16}$) complex at 298 K on Agilent DDR2 800 NMR spectrometer. Table S6: The restrains for ψ and ϕ backbone and χ_1 side-chain torsion angles evaluated by TALOS-N program for *apo* $A\beta_{4-16}$ peptide on base ^1H , ^{13}C , and ^{15}N chemical shifts. Table S7: The restrains for ψ and ϕ backbone and χ_1 side-chain torsion angles evaluated by TALOS-N program for Pd($A\beta_{4-16}$) peptide on base ^1H , ^{13}C , and ^{15}N chemical shifts. Figure S1: $A\beta_{4-16}$ Tyr10 fluorescence ($\lambda_{ex} = 280$ nm, $\lambda_{em} = 303$ nm) quenching by Cu(II) (red dots) and Pd(II) (blue circles). Regions corresponding to the binding of the first and second metal ion equivalent are marked by dashed lines. $[A\beta] = 25$ μM , $[\text{HEPES}] = 20$ mM, pH 7.4 Figure S2: $A\beta_{4-16}$ Tyr10 fluorescence ($\lambda_{ex} = 280$ nm, $\lambda_{em} = 290$ –400 nm) quenching by Cu(II) (A,C) and Pd(II) (B,D). The changes were observed at pH 6.5 (20 mM MES, A,B) and 7.4 (20 mM HEPES, C,D). Shown are the spectra of the peptide with increasing concentrations of Cu(II) or Pd(II) ions. The concentration of $A\beta_{4-16}$ was constant (25 μM), and the concentrations of metal ions were as follows: 0, 4, 8, 12, 16, 18, 20, 22, 24, 26, 28, 30, 32, 36, 40, 44, 52, 60, 80, and 100 μM . Figure S3: The ^1H - ^{15}N HSQC spectrum acquired for Pd($A\beta_{4-6}$) complex at 298 K. The experiments were performed on natural abundance of the ^{15}N isotope Varian Inova 500 NMR spectrometer. Figure S4: The values of (A) longitudinal (R_1) and (B) transverse (R_2) ^{13}C relaxation rates measured for aromatic carbons in Phe4 and His6 in the $A\beta_{4-6}$ peptide for *apo* (red) and Pd(II) (blue) forms. The examples of fit relaxation data for His6 $^{13}\text{C}^{\delta 2}$ in $A\beta_{4-6}$ in complex with Pd(II) presented on panels (C,D) for ^{13}C R_1 and R_2 relaxation rates, respectively. The measurements were performed on the natural abundance of ^{13}C isotope utilizing on Varian Inova 500 NMR spectrometer. Figure S5: The amide-aliphatic part of homonuclear 2D ^1H - ^1H TOCSY spectra for the $A\beta_{4-16}$ peptide acquired with a 80 ms mixing time for *apo* (A) and Pd($A\beta_{4-16}$) saturated (B) forms on an Agilent DDR2 800 NMR spectrometer at 293 K. The assignments in both forms are presented as one-letter code and sequence number. In the case of the Pd($A\beta_{4-16}$) saturated form, signals (Asp7, Ser8, Gly9, Tyr10) representing the *apo* $A\beta_{4-16}$ peptide are clearly visible. The whole assignments yielded by the analysis of NMR data are presented in Tables S4 and Table S5 for the *apo* and Pd($A\beta_{4-16}$) form, respectively. Figure S6: Ensemble of 20 low-energy structures of $A\beta_{4-16}$ peptide in *apo* form evaluated on the base NMR data. The structures are fitted on central $^6\text{HSGY}^{10}$ motif. Orientation side-chains of the His6, Asp7, Ser8 and Tyr10 are shown in green.

Author Contributions: Conceptualization, W.B. and T.F.; methodology, S.C.D., J.P., T.F., K.S., and I.Z.; software, K.S., J.P., and I.Z.; validation, J.P., I.Z., T.F., and W.B.; investigation, M.M., K.S., P.S., J.P., I.Z., and T.F.; resources, S.C.D., T.F., K.S., and W.B.; data curation, M.M., K.S., K.B.-A., P.S., T.F., I.Z.; writing—original draft preparation, T.F., I.Z. and W.B.; writing—review and editing, W.B.; visualization, J.P., I.Z., T.F.; supervision, W.B.; funding acquisition, M.M., and W.B. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Polish National Science Centre grant Preludium number 2014/13/N/ST5/01553 tp M.M.

Acknowledgments: Authors thank to David Plonka for help with the synthesis of the $A\beta_{4-16}$ and FRH peptides.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Abbreviations

The following abbreviations are used in this manuscript:

CD	Circular dichroism
ESI-MS	ElectroSpray Ionisation Mass Spectrometry
IMS-MS	Ion-Mobility Spectrometry Mass Spectrometry
DSS	sodium 2,2-dimethyl-2-silapentane-5-sulfonate
PGSE	Pulsed Gradient Spin Echo
NOESY	Nuclear Overhauser Spectroscopy
HSQC	Heteronuclear Single Quantum Correlation spectroscopy
TOCSY	TOTAL Correlation Spectroscopy
ROS	Reactive Oxygen Species
AD	Alzheimer's Disease

References

1. Masters, C.L.; Simms, G.; Weinman, N.A.; Multhaup, G.; McDonald, B.L.; Beyreuther, K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. *Proc. Natl. Acad. Sci. USA* **1985**, *82*, 4245–4249.
2. Masters, C.L.; Multhaup, G.; Simms, G.; Pottgiesser, J.; Martins, R.; Beyreuther, K. Neuronal origin of a cerebral amyloid: Neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. *EMBO J.* **1985**, *4*, 2757–2763.
3. Lewis, H.; Beher, D.; Cookson, N.; Oakley, A.; Piggott, M.; Morris, C.; Jaros, E.; Perry, R.; Ince, P.; Kenny, R.; et al. Quantification of Alzheimer pathology in ageing and dementia: age-related accumulation of amyloid- β (42) peptide in vascular dementia. *Neuropathol. Appl. Neurobiol.* **2006**, *32*, 103–118.
4. Portelius, E.; Bogdanovic, N.; Gustavsson, M.K.; Volkman, I.; Brinkmalm, G.; Zetterberg, H.; Winblad, B.; Blennow, K. Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. *Acta Neuropathol.* **2010**, *120*, 185–193.
5. Bouter, Y.; Dietrich, K.; Wittnam, J.L.; Rezaei-Ghaleh, N.; Pillot, T.; Papot-Couturier, S.; Lefebvre, T.; Sprenger, F.; Wirths, O.; Zweckstetter, M.; et al. N-truncated amyloid β ($A\beta$) 4-42 forms stable aggregates and induces acute and long-lasting behavioral deficits. *Acta Neuropathol.* **2013**, *126*, 189–205.
6. Wirths, O.; Walter, S.; Kraus, I.; Klafki, H.W.; Stazi, M.; Oberstein, T.J.; Ghiso, J.; Wiltfang, J.; Bayer, T.A.; Weggen, S. N-truncated $A\beta$ 4-x peptides in sporadic Alzheimer's disease cases and transgenic Alzheimer mouse models. *Alzheimer's Res. Ther.* **2017**, *9*, 80.
7. Cabrera, E.; Mathews, P.; Mezhericher, E.; Beach, T.G.; Deng, J.; Neubert, T.A.; Rostagno, A.; Ghiso, J. $A\beta$ truncated species: Implications for brain clearance mechanisms and amyloid plaque deposition. *Biochim. Biophys. Acta BBA Mol. Basis Dis.* **2018**, *1864*, 208–225.
8. Wirths, O.; Zampar, S.; Weggen, S. N-Terminally Truncated $A\beta$ Peptide Variants in Alzheimer's Disease. *Exon Publ.* **2019**, 107–122, doi:10.15586/alzheimersdisease.2019.ch7.
9. Zampar, S.; Klafki, H.W.; Sritharen, K.; Bayer, T.A.; Wiltfang, J.; Rostagno, A.; Ghiso, J.; Miles, L.A.; Wirths, O. N-terminal heterogeneity of parenchymal and vascular amyloid- β deposits in Alzheimer's disease. *Neuropathol. Appl. Neurobiol.* **2020**, *46*, 673–685.
10. Wirths, O.; Zampar, S. Emerging roles of N- and C-terminally truncated $A\beta$ species in Alzheimer's disease. *Expert Opin. Ther. Targets* **2019**, *23*, 991–1004.
11. Alies, B.; Renaglia, E.; Rózga, M.; Bal, W.; Faller, P.; Hureau, C. Cu(II) affinity for the Alzheimer's peptide: Tyrosine fluorescence studies revisited. *Anal. Chem.* **2013**, *85*, 1501–1508.
12. Drew, S.C.; Barnham, K.J. The heterogeneous nature of Cu^{2+} interactions with Alzheimer's amyloid- β peptide. *Accounts Chem. Res.* **2011**, *44*, 1146–1155.
13. Arrigoni, F.; Prodocimi, T.; Mollica, L.; De Gioia, L.; Zampella, G.; Bertini, L. Copper reduction and dioxygen activation in Cu-amyloid beta peptide complexes: Insight from molecular modelling. *Metallomics* **2018**, *10*, 1618–1630.

14. Atrián-Blasco, E.; del Barrio, M.; Faller, P.; Hureau, C. Ascorbate oxidation by Cu (amyloid- β) complexes: Determination of the intrinsic rate as a function of alterations in the peptide sequence revealing key residues for reactive oxygen species production. *Anal. Chem.* **2018**, *90*, 5909–5915.
15. Huang, H.; Lou, X.; Hu, B.; Zhou, Z.; Chen, J.; Tian, Y. A comprehensive study on the generation of reactive oxygen species in Cu-A β -catalyzed redox processes. *Free Radic. Biol. Med.* **2019**, *135*, 125–131.
16. Mital, M.; Wezynfeld, N.E.; Fraczyk, T.; Wiloch, M.Z.; Wawrzyniak, U.E.; Bonna, A.; Tumpach, C.; Barnham, K.J.; Haigh, C.L.; Bal, W.; et al. A functional role for A β in metal homeostasis? N-truncation and high-affinity copper binding. *Angew. Chem.* **2015**, *127*, 10606–10610.
17. Esmieu, C.; Ferrand, G.; Borghesani, V.; Hureau, C. N-truncated A β peptides impact on Cu and Cu (A β)-generated ROS: Cu(I) matters! *Chem. Eur. J.* **2020**, *26*, doi: 10.1002/chem.202003949.
18. Bossak-Ahmad, K.; Mital, M.; Płonka, D.; Drew, S.C.; Bal, W. Oligopeptides generated by neprilysin degradation of β -amyloid have the highest Cu(II) affinity in the whole A β family. *Inorg. Chem.* **2018**, *58*, 932–943.
19. Wezynfeld, N.E.; Stefaniak, E.; Stachucy, K.; Drozd, A.; Płonka, D.; Drew, S.C.; Krężel, A.; Bal, W. Resistance of Cu (A β 4–16) to Copper Capture by Metallothionein-3 Supports a Function for the A β 4–42 Peptide as a Synaptic CuII Scavenger. *Angew. Chem. Int. Ed.* **2016**, *55*, 8235–8238.
20. Santoro, A.; Wezynfeld, N.E.; Vašák, M.; Bal, W.; Faller, P. Cysteine and glutathione trigger the Cu–Zn swap between Cu(II)-amyloid- β 4-16 peptide and Zn 7-metallothionein-3. *Chem. Commun.* **2017**, *53*, 11634–11637.
21. Stefaniak, E.; Bal, W. CuII Binding Properties of N-Truncated A β Peptides: In Search of Biological Function. *Inorg. Chem.* **2019**, *58*, 13561–13577.
22. Stefaniak, E.; Płonka, D.; Szczerba, P.; Wezynfeld, N.E.; Bal, W. Copper Transporters? Glutathione Reactivity of Products of Cu–A β Digestion by Neprilysin. *Inorg. Chem.* **2020**, *59*, 4186–4190.
23. Atrián-Blasco, E.; Gonzalez, P.; Santoro, A.; Alies, B.; Faller, P.; Hureau, C. Cu and Zn coordination to amyloid peptides: From fascinating chemistry to debated pathological relevance. *Coord. Chem. Rev.* **2018**, *371*, 38–55.
24. Sigel, H.; Martin, R.B. Coordinating properties of the amide bond. Stability and structure of metal ion complexes of peptides and related ligands. *Chem. Rev.* **1982**, *82*, 385–426.
25. Harford, C.; Sarkar, B. Amino terminal Cu (II)-and Ni (II)-binding (ATCUN) motif of proteins and peptides: Metal binding, DNA cleavage, and other properties. *Accounts Chem. Res.* **1997**, *30*, 123–130.
26. Gonzalez, P.; Bossak, K.; Stefaniak, E.; Hureau, C.; Raibaut, L.; Bal, W.; Faller, P. N-terminal Cu binding motifs Xxx-Zzz-His (ATCUN) and Xxx-His and their derivatives: Chemistry, biology and medicinal applications. *Chem. Eur. J.* **2018**, *24*, 8029–8041.
27. Hureau, C.; Eury, H.; Guillot, R.; Bijani, C.; Sayen, S.; Solari, P.L.; Guillon, E.; Faller, P.; Dorlet, P. X-ray and Solution Structures of Cu^{II}GHK and Cu^{II}DAHK Complexes: Influence on Their Redox Properties. *Chem. Eur. J.* **2011**, *17*, 10151–10160.
28. Camerman, N.; Camerman, A.; Sarkar, B. Molecular design to mimic the copper (II) transport site of human albumin. The crystal and molecular structure of copper (II)-glycylglycyl-L-histidine-N-methyl amide monoquo complex. *Can. J. Chem.* **1976**, *54*, 1309–1316.
29. Donaldson, L.W.; Skrynnikov, N.R.; Choy, W.Y.; Muhandiram, D.R.; Sarkar, B.; Forman-Kay, J.D.; Kay, L.E. Structural characterization of proteins with an attached ATCUN motif by paramagnetic relaxation enhancement NMR spectroscopy. *J. Am. Chem. Soc.* **2001**, *123*, 9843–9847.
30. Nair, N.G.; Perry, G.; Smith, M.A.; Reddy, V.P. NMR studies of zinc, copper, and iron binding to histidine, the principal metal ion complexing site of amyloid- β peptide. *J. Alzheimer's Dis.* **2010**, *20*, 57–66.
31. Bal, W.; Djuran, M.I.; Margerum, D.W.; Gray, E.T.; Mazid, M.A.; Tom, R.T.; Nieboer, E.; Sadler, P.J. Dioxygen-induced decarboxylation and hydroxylation of [NiII (glycyl-glycyl-L-histidine)] occurs via Ni III: X-ray crystal structure of [NiII (glycyl-glycyl- α -hydroxy-D,L-histamine)]· 3 H₂O. *J. Chem. Soc. Chem. Commun.* **1994**, *16*, 1889–1890.
32. Bal, W.; Chmurny, G.N.; Hilton, B.D.; Sadler, P.J.; Tucker, A. Axial hydrophobic fence in highly-stable Ni(II) complex of des-angiotensinogen N-terminal peptide. *J. Am. Chem. Soc.* **1996**, *118*, 4727–4728.
33. Best, S.L.; Chattopadhyay, T.K.; Djuran, M.I.; Palmer, R.A.; Sadler, P.J.; Sóvágó, I.; Varnagy, K. Gold(III) and Palladium(II) Complexes of Glycylglycyl-L-Histidine: Crystal Structures of [AuIII (Gly-Gly-L-His-H₂)] Cl· H₂O and [PdII (Gly-Gly-L-His-H₂)]· 1.5 H₂O and HiseNH deprotonation. *J. Chem. Soc. Dalton Trans.* **1997**, 2587–2596.

34. Klein, A.; Tsvieriotis, P.; Malandrinos, G.; Hadjiliadis, N. Platinum (II) and palladium (II) complexes with histidine and histidyl containing peptides: Structure and reactivity. *Rev. Inorg. Chem.* **2000**, *20*, 305–338.
35. Frias, E.C.; Pitsch, H.; Ly, J.; Poitrenaud, C. Palladium complexes in concentrated nitrate and acid solutions. *Talanta* **1995**, *42*, 1675–1683.
36. van Middlesworth, J.M.; Wood, S.A. The stability of palladium (II) hydroxide and hydroxy–chloride complexes: An experimental solubility study at 25–85 C and 1 bar. *Geochim. Cosmochim. Acta* **1999**, *63*, 1751–1765.
37. Milić, N.B.; Bugarčić, Ž.D. Hydrolysis of the palladium (II) ion in a sodium chloride medium. *Transit. Met. Chem.* **1984**, *9*, 173–176.
38. Torapava, N.; Elding, L.I.; Mändar, H.; Roosalu, K.; Persson, I. Structures of polynuclear complexes of palladium (II) and platinum (II) formed by slow hydrolysis in acidic aqueous solution. *Dalton Trans.* **2013**, *42*, 7755–7760.
39. Boily, J.F.; Seward, T.M.; Charnock, J.M. The hydrolysis and precipitation of Pd (II) in 0.6 mol kg⁻¹ NaCl: A potentiometric, spectrophotometric, and EXAFS study. *Geochim. Cosmochim. Acta* **2007**, *71*, 4834–4845.
40. Krieger, E.; Koraimann, G.; Vriend, G. Increasing the precision of comparative models with YASARA NOVA—a self-parameterizing force field. *Proteins Struct. Funct. Bioinform.* **2002**, *47*, 393–402.
41. Shen, Y.; Bax, A. Protein structural information derived from NMR chemical shift with the neural network program TALOS-N. In *Artificial Neural Networks*; Springer: Berlin/Heidelberg, Germany, 2015; pp. 17–32.
42. Stejskal, E.O.; Tanner, J.E. Spin diffusion measurements: Spin echoes in the presence of a time-dependent field gradient. *J. Chem. Phys.* **1965**, *42*, 288–292.
43. Macchioni, A.; Ciancaleoni, G.; Zuccaccia, C.; Zuccaccia, D. Determining accurate molecular sizes in solution through NMR diffusion spectroscopy. *Chem. Soc. Rev.* **2008**, *37*, 479–489.
44. Taube, M.; Pietralik, Z.; Szymanska, A.; Szutkowski, K.; Clemens, D.; Grubb, A.; Kozak, M. The domain swapping of human cystatin C induced by synchrotron radiation. *Sci. Rep.* **2019**, *9*, 8548.
45. Bal, W.; Wójcik, J.; Maciejczyk, M.; Grochowski, P.; Kasprzak, K.S. Induction of a secondary structure in the N-terminal pentadecapeptide of human protamine HP2 through Ni(II) coordination. An NMR study. *Chem. Res. Toxicol.* **2000**, *13*, 823–830.
46. Kozłowski, H. Spectroscopic and magnetic resonance studies on Ni(II), Cu(II) and Pd(II) complexes with Gly-Leu-Tyr and Tyr-Gly-Gly tripeptides. *Inorganica Chim. Acta* **1978**, *31*, 135–140.
47. Kozłowski, H.; Jeżowska, M.; Szyszuk, H. PMR conformational studies of Pd(II) complexes with Ala-Tyr and d-Leu-Tyr depeptides. *J. Mol. Struct.* **1978**, *50*, 73–80.
48. Yamauchi, O. Noncovalent interactions in biocomplexes. *Phys. Sci. Rev.* **2016**, *1*, doi:10.1515/psr-2016-0001.
49. Stefaniak, E.; Atrian-Blasco, E.; Goch, W.; Sabater, L.; Hureau, C.; Bal, W. The aggregation pattern of Aβ1-40 is altered by the presence of N-truncated Aβ4-40 and/or Cu(II) ions in a similar way via ionic interactions. *Chem. Eur. J.* **2020**, in press.
50. Wishart, D.S.; Bigam, C.G.; Yao, J.; Abildgaard, F.; Dyson, H.J.; Oldfield, E.; Markley, J.L.; Sykes, B.D. ¹H, ¹³C and ¹⁵N chemical shift referencing in biomolecular NMR. *J. Biomol. NMR* **1995**, *6*, 135–140.
51. Delaglio, F.; Grzesiek, S.; Vuister, G.W.; Zhu, G.; Pfeifer, J.; Bax, A. NMRPipe: A multidimensional spectral processing system based on UNIX pipes. *J. Biomol. NMR* **1995**, *6*, 277–293.
52. Lee, W.; Tonelli, M.; Markley, J.L. NMRFAM-SPARKY: Enhanced software for biomolecular NMR spectroscopy. *Bioinformatics* **2015**, *31*, 1325–1327.
53. Schwieters, C.D.; Kuszewski, J.J.; Clore, G.M. Using Xplor-NIH for NMR molecular structure determination. *Prog. Nucl. Magn. Reson. Spectrosc.* **2006**, *48*, 47–62.
54. Koradi, R.; Billeter, M.; Wüthrich, K. MOLMOL: A program for display and analysis of macromolecular structures. *J. Mol. Graph.* **1996**, *14*, 51–55.
55. Pettersen, E.F.; Goddard, T.D.; Huang, C.C.; Couch, G.S.; Greenblatt, D.M.; Meng, E.C.; Ferrin, T.E. UCSF Chimera—a visualization system for exploratory research and analysis. *J. Comput. Chem.* **2004**, *25*, 1605–1612.

56. Wu, D.; Chen, A.; Johnson, C.S. An improved diffusion-ordered spectroscopy experiment incorporating bipolar-gradient pulses. *J. Magn. Reson. Ser. A* **1995**, *115*, 260–264.
57. Hwang, T.L.; Shaka, A. Water suppression that works. Excitation sculpting using arbitrary wave-forms and pulsed-field gradients. *J. Magn. Reson. Ser. A* **1995**, *112*, 275–279.

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).